News

FDA Solicits Feedback on Drug Products Approved Under Abbreviated New Drug Applications Before the Enactment of the Hatch-Waxman Amendments

The FDA has established a public docket to solicit comments on several issues related to FDA’s regulation of certain drug products approved under abbreviated new drug applications before the enactment of the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. Because these Pre-Hatch-Waxman ANDAs (PANDAs) were submitted under section 505(b) and approved under section 505(c) of the Federal Food, Drug, and Cosmetic (FD&C) Act, they can serve as a reference listed drug (RLD) for future abbreviated new drug applications submitted under section 505(j) of the FD&C Act (505(j) ANDAs) and can also be a listed drug relied on by 505(b)(2) applications.

Although these PANDAs are 505(b) applications, they have historically been overseen by FDA’s Office of Generic Drugs. FDA is aware that there may be some confusion about the applicability of certain statutory and regulatory provisions to these PANDAs. In particular, there is confusion whether PANDAs are subject to the requirements that apply to other 505(b) applications or to those that apply to 505(j) applications. FDA recognizes there are differences between certain requirements for 505(b) application and 505(j) applications, including with respect to requirements regarding labeling updates, patent listing, eligibility for exclusivity, and certain drug safety-related requirements or procedures.

FDA is seeking input from holders of these PANDAs and other interested persons regarding whether there are regulatory or policy rationales for treating these PANDAs differently from other 505(b) applications in certain respects. To facilitate stakeholder feedback, FDA has included specific questions in the Federal Register Notice. These questions are not meant to be exhaustive, and FDA is also interested in any other pertinent information stakeholders would like to share on this topic. In all cases, FDA encourages stakeholders to provide the rationale and basis for their comments, including any available supporting data and information. Interested persons can submit comments to the docket until December 11, 2021.

Recent News

09/03/2025

Cupron Performance Additives (“Cupron”) announces new distribution relationship with Palmer Holland

Cupron Performance Additives (Cupron) announced today the launch of an exclusive distribution agreement with Palmer Holland, leading North American distributor of specialty additives for the engineered materials marketplace. Palmer Holland will distribute Cupron’s copper-based antimicrobial and anti-odor technologies into plastics, films, foams, and polymeric systems throughout North America. The Cupron line effectively complements Palmer Holland’s

08/26/2025

Activation Capital Names Michael Steele as President and CEO

The Virginia Biotechnology Research Partnership Authority (doing business as Activation Capital) announced today that it has appointed Michael Steele as president and chief executive officer. Steele succeeds Robert Ward, who has served as interim CEO since July 2024 during a period of rapid growth for the life sciences ecosystem development organization. Steele comes to Activation

08/25/2025

Danforth Advisors Acquires PharmaDirections

Danforth Advisors LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization. Founded in 2003, PharmaDirections was a pioneer of the virtual drug development model. The company brings veteran program leaders and more than 150 specialists to support strategic planning and